Data protection Impressum

Personalized Medicine

The inclusion of Aktiia’s technology in the GAPP study is a testament to its potential in reshaping blood pressure research.

Aktiia’s blood pressure monitoring technology advances global cardiovascular research

14 November 2023

Empa is one of the partners who established the new "Dynamic Imaging Center" (DIC) in Bern.

Opening of the Dynamic Imaging Center at sitem-insel in Bern

13 November 2023

From left to right: Christoph Ammann, Canton of Bern - Dr. med. h.c. Uwe E. Jocham, Insel Gruppe - Prof. Dr. Christian Leumann, University of Bern - Dr. Alexandre Pauchard, CSEM, Jens Krauss, CSEM.

Bern’s journey to becoming a world-class medtech hub by 2030

9 November 2023

Novochizol technology quantitatively transforms single linear chitosan molecules into cross-linked, uniformly sized nanospheres.

EPFL and Novochizol to collaborate on designing more efficient immunotherapies

2 November 2023

The Institute of Tissue Medicine and Pathology of the University of Bern covers the entire width of the morphological and molecular diagnostics of tissue samples. | © University of Bern

A new gel offers targeted relief for ulcerative colitis patients

2 November 2023

NASA will use Compremium's CPMX1 System for extended space voyages to the Moon and Mars, aiming to safeguard astronaut well-being throughout extended zero-gravity journeys.

Compremium’s breakthrough medical device embarks on a NASA voyage

25 October 2023

From left to right: Prof. Han (Professor of Yonsei Cancer Center), Dr. Chun (CSO of Oncosoft), Prof. Dong Wook Kim (Clinical Professor, Yonsei Cancer Center), Laura Acosta (Swiss Embassy Representative), Prof. Ik Jae Lee (Director of Heavy Ion Therapy, Yonsei Cancer Center), Dr. Christina Vallgren (CEO of Terapet), Herve Duffour (Sales and Marketing director of Terapet), Prof. Jin Sung Kim (Chief Medical Physicist of Yonsei Cancer Center & CEO of Oncosoft).

Terapet enters partnership with Korean entities for its breakthrough cancer therapy device

18 October 2023

Mimix’s objective, as outlined in its strategic vision, is to introduce this wound care product to the US market by the second half of 2024.

Mimix Biotherapeutics’ breakthrough tissue regeneration treatment receives strategic investment

17 October 2023

From left to right: Nicolas Weber, CEO of Voltiris, Nasri Nahas, CEO of Biopôle SA, Jonas Roch, CTO of Voltiris and Pierre-Jean Wipff, Innovation and Partnerships Director at Biopôle.

Voltiris, Limula, and Parithera secure Biopôle’s Start-Up Fund

11 October 2023

Top Stories Western Switzerland

Top Stories from Western Switzerland (July-September 2023)

27 September 2023

1 … 5 6 7 8 9 10 11 12 13 … 17